Search

Grants

LRF awards grants in a number of key areas.  Please check dates for each RFP as not all those listed are currently open for new applications.

  1. Training and recruiting junior researchers:
  2. Focus Area Grants

Engaging and Educating Junior Researchers

Post-Doctoral Fellowships and Clinical Investigator Career Development Awards are central to our mission and represent our two Cornerstone Research Programs. These programs attract young physicians to the field of lymphoma and support their training in lymphoma and clinical research. The National Institutes of Health (NIH) and National Cancer Institute (NCI) cite the training of clinical investigators and translational researchers in their Roadmap for how to improve health and alleviate suffering from disease. The Lymphoma Research Foundation shares this priority. The LRF is proud that since 1992 we have awarded 208 Fellowships, while since 2002, we have awarded 12 Clinical Career Development Awards.

Post-Doctoral Fellowships

These two-year fellowships help attract the nation's best scientific talent to careers in lymphoma and allow them to pursue promising leads under the guidance of a Sponsor. Applicants must be affiliated with an institution in the U.S. or Canada. Fellowships are awarded at $50,000 in year one and $55,000 in year two.

Clinical Investigator Career Development Awards (CDAs)

This three-year program (now with recently expanded eligibility) funds training of clinicians who will participate in developing new therapeutics and diagnostic tools for lymphoma. Clinicians will be trained to design and administer clinical studies and to take on primary responsibility for trial design, protocol development, IRB submission, and publication. A Career Development Plan and the commitment of a mentor are required as part of the grant application. Up to three CDAs will be awarded, each at a maximum of $75,000 per year for three years. Applicants must be licensed in the U.S. or Canada.

Focus Areas

Major Research Grants for Senior Researchers: These are awarded to experienced researchers pursuing the development of novel and innovative treatments.

Chronic Lymphocytic Leukemia (CLL) Collaborative Grant

The Lymphoma Research Foundation (LRF) CLL Consortium sought proposals for its 2-year CLL Collaborative Grant for high quality research studies in CLL. Applications to this initiative were required to include the study of primary CLL/MBL patient samples to assure relevance to the human disease. In addition, applicants were required to explicitly delineate how the proposed research would incorporate collaborative interactions between/among investigators in different disciplines (e.g. pathology & medical oncology, basic science research & clinical investigators) and/or different institutions.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

This LRF initiative (started in 2006) aims to develop novel therapeutic strategies for the treatment of CLL/SLL by funding projects that advance the understanding of the human biology of this disease and/or that verify molecular targets for CLL/SLL therapeutics. In 2006-2007, funding was available for up to three years, for a maximum of $250,000 per year plus overhead (up to 25%). Future CLL/SLL grant opportunities are dependent on the availability of funds. Please visit the website later this year for possible new grant announcements in this focus area.

Diffuse Large B-Cell Lymphoma (DLBCL) Collaborative Grant

The Lymphoma Research Foundation (LRF) DLBCL Consortium sought proposals for its 2-year DLBCL Explorations Grant for high quality research studies in DLBCL. Applications to this initiative were expected to include the study of primary DLBCL patient samples. Proposals were to include a clear indication of how the project would be clinically relevant to the improvement of outcomes for patients with DLBCL. Applicants were encouraged to describe how they would leverage other resources (funding support, institutional resources, clinical trial samples, etc.) in carrying out the project. In addition, applicants were required to delineate how the proposed research project would involve collaborative interactions between/among investigators in different disciplines (e.g. pathology & hematology/oncology, basic science research & clinical investigators) and/or different institutions.

Follicular Lymphoma (FL) Pathways Grant

The Lymphoma Research Foundation (LRF) Follicular Lymphoma Consortium sought proposals for its 3-year FL Pathways Grant for high quality research studies in FL. Applications to this initiative were required to include the study of primary FL patient samples to assure relevance to the human disease. In addition, applicants were required to explicitly delineate how the proposed research would incorporate collaborative interactions between/among investigators in different disciplines (e.g. pathology & medical oncology, basic science research & clinical investigators) and/or different institutions.

Follicular Lymphoma

The goal of LRF's Follicular Lymphoma (FL) Research Initiative is to develop novel therapeutic strategies for the treatment of FL. LRF is seeking proposals that advance the understanding of the human biology of FL or that verify molecular targets for FL therapeutics. LRF is awarding two grants for this special research initiative, each at a maximum of $250,000 per year for three years.

Follicular Lymphoma Correlative Clinical Studies Award

LRF is also seeking proposals for correlative clinical studies in follicular lymphoma (FL). Applications to this initiative must be adjunct to a major FL research project and work in the clinical setting or with primary FL patient samples. LRF is awarding two correlative clinical study awards, each at a maximum of $125,000 per year for three years.

Future Funding Opportunities: LRF is currently fundraising to support additional grants in the following areas. Visit the website later this year for possible new grant announcements.

Mantle Cell Lymphoma (MCL)

In 2003, LRF started the Mantle Cell Lymphoma Initiative to accelerate the pace of research in mantle cell lymphoma (MCL). LRF-funded MCL research projects have ranged from laboratory studies to the identification of new therapeutic approaches, including clinical trials of novel agents, chemo immunotherapy, radiation therapy and stem cell transplantation. Previously, funding for this initiative has been up to $250,000 plus overhead (up to 25%), for up to three years duration. International applications from licensed researchers were accepted. Future MCL grant opportunities are dependent on the availability of funds.  Please visit the website later this year for grant announcements in this focus area.

Requests for further information should be directed to researchgrants@lymphoma.org.

NOTE: Lymphoma Research Foundation reserves the right to change deadlines, forms, and guidelines, plus any and all details pertaining to grant availability, rules, eligibility criteria, selection process, etc. All LRF Research Grants are dependent on funding availability.

If you would like to learn more about how you can invest in lymphoma research, please contact 800-235-6848.